Serum LEAP2 Levels Across the Spectrum of Metabolic Dysfunction-Associated Fatty Liver Disease: A Potential Noninvasive Biomarker for Severity Stratification

Xinyang Huang,1,* Zihao Deng,1,* Xiaozhou Li,2 Songxin Yan,3 Kunjiang Zhong,1 Fengning Yuan,4 Ligang Liu,5 Chaolin Deng,6 Tingting Liu,7 Ruizhao Zhao,1 Amin Buhe,2 Tianxiong Li,2 Hao Zhao2 1Capital Medical University, Beijing, People’s Republic of China; 2Surgery Centre of Diabetes M...

Ful tanımlama

Detaylı Bibliyografya

Asıl Yazarlar:	Huang X, Deng Z, Li X, Yan S, Zhong K, Yuan F, Liu L, Deng C, Liu T, Zhao R, Buhe A, Li T, Zhao H
Materyal Türü:	Artigo
Dil:	Inglês
Baskı/Yayın Bilgisi:	Dove Medical Press 2025-07-01
Seri Bilgileri:	Diabetes, Metabolic Syndrome and Obesity
Konular:	LEAP2 MAFLD MASH hepatic steatosis biomarker
Online Erişim:	https://www.dovepress.com/serum-leap2-levels-across-the-spectrum-of-metabolic-dysfunction-associ-peer-reviewed-fulltext-article-DMSO
Etiketler:	Etiketle Etiket eklenmemiş, İlk siz ekleyin!